MGNX vs SNDX
MGNX: Clinical-stage biopharmaceutical company developing innovative antibody-based cancer therapeutics using proprietary DART, TRIDENT, and ADC platforms. SNDX: Syndax Pharmaceuticals is a clinical-stage and commercial-stage biotechnology company developing a pipeline of targeted cancer therapies, including approved treatments for leukemia and chronic graft-versus-host disease.
Side-by-side fundamentals
| Metric | MGNX | SNDX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.30 | $22.05 | |
| Market cap as of 2026-07-23 | $289M | $2.0B | |
| PEG as of 2026-07-23 | -0.16 | n/a | |
| Net margin as of 2026-07-23 | -44.8% | -111.9% | MGNX higher |
| Gross margin as of 2026-07-23 | +74.5% | +96.0% | SNDX higher |
| Operating margin as of 2026-07-23 | -40.5% | -102.8% | MGNX higher |
| ROE as of 2026-07-23 | -147.8% | -256.7% | MGNX higher |
| ROA as of 2026-07-23 | -28.4% | -45.3% | MGNX higher |
| Debt / equity as of 2026-07-23 | 3.24 | 8.26 | MGNX lower |
| Revenue growth (YoY) as of 2026-07-23 | +2.0% | +397.3% | SNDX higher |
| Revenue CAGR (3y) SEC XBRL | -0.5% | n/a | |
| Beta as of 2026-07-23 | 1.19 | 0.35 | |
| 1-year return as of 2026-07-22 close | +179.2% | +113.9% | MGNX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.